THE TREATMENT OF AUTOIMMUNE DISEASE USING 2-AMINO PURINE DERIVATIVES

Abstract: A method for treating autoimmune disease, or the pain and/or insomnia associated with autoimmune disease, in a mammalian subject, particularly a human, which method comprises administering a therapeutically effective amount of certain 2-amino purine compounds to the subject. The compounds particularly useful are antiviral compounds exemplified by acyclovir, valacyclovir, penciclovir and famciclovir. The compounds are administered at doses significantly higher (4 to 12 times) than the dose level currently approved and used to treat currently recognized manifestations of viral infections. Currently approved doses result in blood levels of about 0.5-1.0 micrograms/ml. This new technique results in blood levels of about 3-10 micrograms/ml with about 6 micrograms per ml being optimal.

Description: THE TREATMENT OF AUTOIMMUNE DISEASE USING 2-AMINO PURINE DERIVATIVES 10 Field of the Invention The present invention relates to the use of 2-amino purine derivatives to treat autoimmune disease(s), particularly the inflammation, tissue destruction caused by the inflammation and the pain of autoimmune diseases and related autoimmune 15 conditions. Background of the Invention US Patent 4,199,574 issued April 27, 1980 to Shaeffer describes a broad class of 6- and 2, 6-substituted purine derivatives containing an acyclic side chain 20 (particularly hydroxyethoxymethyl) in the 9 position that were found to have antiviral activity against various classes of DNA viruses, particularly against herpes viruses such as herpes simplex. Among these derivatives, 9-(2- hydroxyethoxymethyl) guanine (generically known as acyclovir) has been found to have particularly good activity against herpes simplex viruses. 25 It is also known that the glycine, alanine, and valine esters of acyclovir show improved water solubility as compared to acyclovir itself and that the valine ester (valacyclovir) has improved bioavailability as compared to the glycine or alanine esters. See for example U.S. 4,957,924, issued September 18, 1990 to Beauchamp and European Patent Specification 99493. 30 It is also known that a related class of purine derivatives characterized by the presence of a hydrogen atom in the 6 position of the purine nucleus is converted in vivo by the action of the molybdo-flavo-protein enzymes xanthine oxidase/dehydrogenase or aldehyde oxidase into the corresponding 6 hydroxypurine compound acyclovir. The 6-hydrogen compounds are disclosed in U.S. Patent 35 5,059,604, issued October 22, 1991 to Krenitsky and Beauchamp. Another compound that is known to be useful for treating the viruses in the herpes simplex family is a compound called famciclovir chemically known as 2-[2- (2-amino-9H-purin-9-yl)ethyl]-l ,3-propanediol diacetate. This compound is a prodrug of the antiviral agent penciclovir, which is the corresponding analog of famciclovir where there is a hydroxy at the 6 position in the purine ring instead of a hydrogen. The chemical name of penciclovir is 9-(4-hydroxy-3-hydroxymethyl-l- butyl)guanine. These and related compounds are described in U.S. Patents 5,246,937 issued September 21, 1993; 5,250,688 issued October 5, 1993; and U.S. 5,075,445 issued December 24, 1991. All of the above-mentioned patents and applications are incorporated herein by reference. The Food and Drug Administration (FDA) currently approves acyclovir and penciclovir for the treatment of vesicle outbreaks of HSN I and HSV π. Famciclovir is FDA approved for the treatment of the vesicle outbreak phase of herpes zoster. Such treatment requires blood levels between 0.5 microgram/milliliter ( gm/ml) and 1.0 μgm/ml for acyclovir and similar levels for famciclovir. The currently recognized oral doses required to reach this blood level for an adequate amount of time (which varies according to the virus being treated and is based upon the effective half-life of the drug) for reasonable therapeutic effect are as follows: 1. Famvir ® brand famciclovir is only approved for use against Zoster at the oral doses of 500 mg three times per day. The absorption is linear in this dose range. 2. Zovirax ® brand acyclovir is approved for several different uses against several different presentations of herpes viruses at oral doses that range between 200 mg three times per day and 800 mg 5 times per day. Because the absorption of acyclovir is non-linear in this dose range Burroughs- Wellcome, the manufacturer, has strongly discouraged the use of higher doses because it believes little more can be absorbed with doses higher than the maximum dose of 800 mg 5 times per day, which in most patients gives a blood level near 1 μmg/ml. 3. Valtrex ® brand valacyclovir is approved for the treatment of herpes zoster (shingles) in immunocompetent patients at a dosage of 1 gram (two 500 mg caplets) orally three times daily for 7 days. Valacyclovir is a pro-drug for acyclovir. Autoimmune disorders are conditions in which the body's immune system produces antibodies to the body's own tissues (i.e., endogenous antigens). This attack on the body is the reason for the names autoimmune and autoantibody. 5 Although, much is known about these diseases, the etiology of all of them is unknown as is the relationship between the various autoimmune disease conditions. It is known that in the most severe cases there is demonstrable antibody to otherwise apparently normal body tissue (i.e., autoantigens). However, there is a large spectrum of autoimmune-associated conditions that frequently occur in patients 10 without demonstrable circulating autoantibodies. These include the myofascial pain syndrome, the irritable bowel syndrome, interstitial cystitis, etc. It is not known to current medical science whether these autoimmune-associated disorders are milder expressions of the same disease processes or totally separate entities. While it is assumed by many researchers in this field that there are causative agents for these 15 conditions, such agents have not heretofore been identified. At least four possible mechanisms are recognized for developing an immune response to auto-antigens. These are briefly discussed in The Merck Manual of Diagnosis and Therapy. Sixteenth Edition. Robert Berkow, M.D. , Editor-in-Chief, 1992, Merck Research Laboratories, chap. 20. Many diseases that are thought to 20 belong to this family of disorders are set forth at p. 340 of the Merck Manual. Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (scleroderma, old name) are major diseases in this category. In the population afflicted with autoimmune disorders there is autoimmune inflammation, tissue destruction and often a very high level of pain. Frequently these signs and 25 symptoms are so debilitating that a subject is so overcome that he or she can't function normally. Drugs for treating autoimmune diseases such as rheumatoid arthritis are set forth in The Medical Letter on Drugs and Therapeutics, vol. 36 (Issue 935), November 11, 1994. All of the current treatments such as non- steroidal anti-inflammatory agents (NSAIDs), steroids, etc. work by directly 30 interfering with and suppressing the body's immune response. They all are inadequate primarily because of the following problems: 1. The current therapies only slow and diminish but do not arrest the inflammatory process and the progression of the autoimmune disease(s). This is because if they were used in a manner to totally suppress the immune system, the result would be the same as AIDS. 2. They frequently have such severe life threatening side effects that their use must be curtailed in the patient with the most severe autoimmune disease. Thus, the patients who need treatment most critically cannot get adequate control of the autoimmune inflammation before the regimen must be curtailed to prevent serious injury or death from the toxic effects of the medications. The side effects of many recognized treatments are too severe for use in "mild" autoimmune disease(s), the cure is often more dangerous than the disease(s) in these circumstances. In accordance with this invention, it has now been found, that by administering certain 2-amino purine derivatives (e.g., certain antiviral compounds) at very high dosages, the signs and symptoms, particularly inflammation, tissue destruction and the pain, associated with autoimmune disorders can be ameliorated to the point where a subject can continue functioning in a normal fashion and the tissue destruction is arrested with no dangerous side effects, though with acyclovir there may be severe discomfort. SUMMARY OF THE INVENTION Broadly this invention may be viewed as a method for treating autoimmune disease in a mammalian subject exhibiting the signs and symptoms of the disease by administering a compound that is active against herpes virus at levels sufficient to prevent the herpes virus from viral shedding, i.e., the non-vesicle, non-cellularly destructive production of low levels of virus. Generally this is a continuous therapy over long time periods that provides a blood level of the compound that suppresses thymidine kinase to block virus production. One aspect of this invention is a method for treating autoimmune disease in a mammalian subject, particularly one that experiences high levels of inflammation, tissue destruction and/or pain associated with such disease, which method comprises administering a therapeutically effective amount of a compound of Formula (I) or Formula (II) to a subject in need thereof. Formula (I) is where A is H or OH and ^ OR is OH, a lower alkyl ester of 2-4 carbon atoms or OC(O)C-R 4 10 H where -R, is H or alkyl of one to four carbons, and Formula (II) is 15 R 1 O-CH 2 -CH-CH 2 -OR 2 wherein 25 B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R[ and R 2 is independently hydrogen, R c - or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or 30 R, and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group. The compound is administered in an amount sufficient to provide the level of such compound in the subject's blood plasma to reduce the subject's inflammation, tissue destruction and/or pain. Another aspect of this invention is a pharmaceutical composition in unit dosage form in combination with labelling instructions for treating autoimmune disease in a mammalian subject wherein (a) the pharmaceutical composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound chosen from those represented by Formula (I) or (II) as set forth above, wherein the components are as defined; and (b) the labelling instructions provide for administering a sufficient amount of the compound to the subject so that the blood plasma level of the active compound results in improvement to the subject's autoimmune disease. Still another aspect of this invention is a method of treating insomnia which is associated with the effects of autoimmune disease in a mammalian subject, which method comprises administering a therapeutically affective amount of a compound of Formula (I) or (II) to a subject in need thereof wherein Formula (I) or Formula (II) are defined above and the components are as defined as well. Still another aspect of this invention is the use of a compound to prepare a pharmaceutical composition for treating autoimmune disease where the compound is represented by Formula (I) or Formula (II), wherein the formulas and their components are defined as set forth above. Still another aspect of this invention is a method for detecting whether a subject exhibiting signs and symptoms of autoimmune disease can be treated to reduce such signs and symptoms by administering a therapeutically effective compound represented by Formula (I) or (II) wherein the formulas and the components are defined above, wherein such method comprises taking a body sample from the subject and detecting the presence or absence of a vims from the herpes simplex family. Detailed Description of the Invention Broadly this invention may be viewed as a method for treating autoimmune disease in a mammalian subject exhibiting the signs and symptoms of the disease by administering a compound that is active against herpes virus at levels sufficient to prevent the herpes virus from viral shedding, i.e., the non-vesicle, non-cellularly 5 destructive production of low levels of virus. Generally this is a continuous therapy over long time periods that provides a blood level of the compound that suppresses thymidine kinase to block virus production. The compounds for use may be any compounds that provide the inhibitory activity. These may be small organic compounds such as the 2-amino purines 10 described hereinafter or large RNA or DNA based molecules that block virus production, e.g., via "antisense" technology. One aspect of the invention is a new method for treating autoimmune disease in a mammalian subject, particularly a human patient who experiences high levels of inflammation, tissue destruction and/or pain associated with such a disease, with a 15 compound of Formula (I) or (II) in an amount sufficient to provide the levels of the compound in the subject's blood plasma to reduce the inflammation, tissue destruction and/or pain level and improve other signs or symptoms. While the mechanism of action is not fully understood as to how the compounds of the invention work, it has been found by providing a subject with a therapeutically 20 effective amount (i.e., extraordinarily high dosages as compared to the levels currently approved for antiviral usage) of the compounds of the invention, the inflammation and other signs and symptoms can be reduced, e.g., by about 80% with acyclovir and by about 90% with famciclovir. Autoimmune disease is meant to encompass those conditions in which the 25 body's immune system produces antibodies to the body's own tissue (i.e. , endogenous antigens). Generally the conditions are associated with inflammation, tissue destruction and pain. Many conditions are included under the autoimmune disease "umbrella" and are set out in the Merck Manual at Chapter 20 and elsewhere. Major diseases include SLE, RA and systemic sclerosis. The latter may 30 occur with or without autoimmune renal destruction and autoimmune associated conditions including but not limited to irritable bowel syndrome, tic douloureux (trigeminal neuralgia), myofascial pain syndrome, interstitial cystitis, Reiter's syndrome, and the like. Also included is multiple sclerosis and chronic non-cancer pain. While some clinicians may consider chronic non-cancer pain as a distinct, unrelated entity, it is included here with the view that some chronic non-cancer pain syndromes are caused by the same mechanism(s) that cause autoimmune disease(s). Some examples are the myofascial pain syndrome and fibromylagia. Patients with autoimmune disease often suffer significant inflammation of the kidneys, often causing renal destruction. The best clinical laboratory measure of kidney function is creatinine clearance. In many cases the kidney function is so reduced that death results. In addition, a significant pain level is often experienced. The pain can be in the joints and the muscles of the back, the esophagus and the bowels (e.g., scleroderma bowel syndrome). The pain level may come and go in spasms which reduces the normal functioning of an individual. Other symptoms that are seen in the autoimmune patients (e.g., rheumatoid arthritis) include the inflammation and tissue destruction of the joints. When this occurs in the hands, the swelling and tissue destruction is sometimes so great that the hands cannot be closed. Another frequent sign in patients with autoimmune disease is the appearance of a "butterfly" rash across the face, particularly in SLE. While the cause(s) of autoimmune diseases or conditions is/are not known, it is believed that there is/are causative agent(s). The current belief is that each individual condition or disease that is included under the umbrella of "autoimmune disease" probably has a different causative factor or etiology. While not wishing to be bound by any theory of operation of the method of this invention, Applicant's invention is based, at least in part, on the concept that most of the individual conditions or diseases included under the classification of autoimmune disease are caused by one or more members of the herpes virus family. While some clinicians consider chronic non-cancer pain as a distinct, unrelated entity, it is included here because: (1) in the literature it has been linked to frank autoimmune disease(s), (2) it has been successfully treated by the inventor using the therapies for which a patent is being sought, and (3) it is consistent with the inventor's theory that each of these entities (autoimmune disease also causes chronic non-cancer pain) are different manifestations of the same mechanism. It is believed that both are caused by the low level production of herpetic virus that does not destroy the producing human cell usually called "viral shedding". Currently most researchers and clinicians do not believe that viral shedding causes any known disease. Most researchers believe only significant disease(s) are those caused by the herpetic vesicle lesions. (This is where the infected cell contents are nearly totally 5 replaced with fluid and virus, the cell expands in size many orders of magnitude and then bursts expelling the contents and finishing the destruction of the cell.) If the cells so destroyed are in the brain this is herpetic encephalitis (usually HSV I or HSV π) and is usually a disaster, often fatal. If the cells are just on the skin such as in Zoster or Simplex vesicles, usually they are of limited duration and healing 10 occurs replacing the destroyed cells. In Zoster it is recognized that persistent chronic pain can occur after the lesions have healed and this is named Post Herpetic neuralgia. The causative mechanism of post herpetic neuralgia is unknown. Recently approval has been given for treatment of this condition with both Acyclovir and Famvir, but in short durations (7-10 days) and at doses much lower 15 than in this invention and it is much less effective than this invention produces. This invention is based upon the inventor's effective treatment of both autoimmune disease signs and symptoms and severe chronic pain syndromes by the use of much higher doses with longer duration than the previously approved recommend doses. It is known that viral shedding (the non-vesicle, non-cellularly destructive 20 production of low levels of virus) is poorly controlled by the currently recommended doses and of course there is no control when the medications are stopped. While not intending to be limited to a particular theory, it is believed that herpetic viral shedding can cause either simultaneously or separately and in varying 25 relative proportions the conditions we know as autoimmune disease(s) and chronic non-cancer pain. The pain is caused by the cellular "irritation" of the nerves caused by the shedding process and the immune response. If this is occurring in many adjacent pain nerves the increased irritability will increase the pain signals to the brain resulting in "trigger" points and areas of hyperesthesia for the parts of the 30 body innervated by the nerves irritated by the shedding. Any pattern of distribution over the patient's anatomy can result, but most often the areas of hyperesthesia are adjacent in terms of their innervation in the sympathetic chain which includes pain nerves and creates responses to pain, including reflex muscle spasm. This causes the clinical entities of chronic pain such as myofascial pain syndrome (pain and hyperesthesia of the skin in localized areas and hypertonus and/or spasm of the muscles [usually underlying] that share the same or adjacent nodes on the sympathetic chain), irritable bowel syndrome (painful spasms of the bowel), interstitial cystitis (painful spasms of the bladder). These are just a few examples. The nomenclature and the literature reflect the lack of a coherent theory of causation as offered here, but is the result of many different medical specialists evaluating and describing conditions of hyperesthesia, hypertonus, hyperreflexia and chronic pain in each specialty's end organ and not looking at the one system that mediates and controls these responses in all organs, the sympathetic nervous system. The current literature appears to be a classic example of the parable of the elephant being described by four blind men. Every specialist looks at the pain and spasm in "his" organ and not the whole picture. Until now no one has developed a unifying theory or an effective treatment as is being claimed herein. Thus, the compounds used in the very high dosages and blood levels set forth herein are useful for treating sympathetic-mediated pain and other effects of sympathetic chain irritation, as distinguished from somatic-mediated pain which conventional doses treat marginally. It is believed that autoimmune disease is also stimulated by the viral shedding. This occurs because the immune system is stimulated by and attacks the virus as it is shed. It is further believed that autoimmune disease is caused by an adjuvant effect or just a stimulant effect that occurs with viral shedding. The adjuvant effect is where antigens that normally do not stimulate an immune system's response can stimulate such a response when another material that is highly stimulative to the immune system is introduced at the same time. The stimulant effect is where the presence of intracellular components in extraordinarily high concentrations outside the cell stimulates the immune system to built antibodies that also inadvertently attack the components of non-disrupted cells. Thus, when the virus particles are shed they cause temporary disruption of the outer cellular membranes and the mitochondria! membranes (the organelles inside the cell that normally has the cellular machinery necessary to reproduce the virus). As the viral particles spill out, components of the temporarily disrupted cellular membranes (these cells recover) are also spilled out and are presented to the immune system in much higher than normal concentrations immediately adjacent to the virus that the immune system is attacking. Either mechanism can result in the sensitization of the 5 * immune system to attack the otherwise normal cellular components, resulting in autoimmune disease(s) and the mechanisms are not mutually exclusive. By administering large chronic doses of compounds such as those of Formula (I) or (II) at levels that maintain blood levels that suppress thymidine kinase to block virus production and stop viral shedding, the chronic pain and autoimmune 10 disease is stopped. This requires doses much higher than currently approved and requires continuous therapy (over months and even years), not the short durations now currently approved (i.e. 7-10 days). Supportive evidence for this theory is seen in a successfully treated patient when the high doses are stopped or lowered to the currently approved levels: all 15 the signs and symptoms of chronic non-cancer pain and autoimmune disease rapidly reoccur. However, these diseases are again suppressed when adequate doses of medications that inhibit viral shedding are restarted. The same process is believed to occur in the tissues of the skin causing scleroderma, the joints causing rheumatoid arthritis, the myelin sheaths causing multiple sclerosis or the atypical 20 demyelination occasionally seen with other autoimmune disease(s). These are just a few examples. Thus the invention is based upon an entirely different approach to the problem of treating autoimmune disease(s). This technique is based upon an attempt to stop the production of the antigens stimulating the autoimmune attack. 25 Under the current theory the immune system is behaving abnormally by attacking normal cells and intracellular membranes. The method of this invention is predicated upon the theory that the normal appearing cells (normal to our current technologies) are infected with viral DNA and are producing viral proteins without self destructing in vesicles, by the slow release of virus (i.e. viral shedding). These 30 viral proteins are "foreign" to the immune system and thus it initiates attack upon them. This results in an "adjuvant effect" for the cell membranes. Thus the immune system begins to attack the normal cell membranes of the nucleus, the mitochondria, the cell wall or other cellular components causing inflammation and tissue destruction. The theory predicts that is the underlying production of "foreign proteins" is suppressed, there will be no longer "adjuvant" stimulation. Then the immune system may diminish or cease it's attack upon the normal membranes. Of all the viruses that have widespread distributions in the human population, the herpes viruses display the most aggressive long term continued testing of the immune system. When the immune system fails or is suppressed a new presentation of the herpetic vesicle phase commonly results. This is not true for measles, and numerous other common viral illnesses. Herpes displays a preference for and an ability to survive in nervous tissue for long periods. Many of the symptoms of autoimmune-associated conditions could be explained by limited focal irritation of the sympathetic nervous system. Some Herpes viruses display the ability to erupt virus filled vesicles on localized areas of the skin that burst releasing virus. This includes shingles caused by varicella-Zoster (VZV) in the area of an infected somatic nerve. Also included are the vesicles of genital herpes and "cold sores" on the face usually caused by HSV π and HSV I respectively; however, because of modern sexual behavior HSV π is now occasionally found on the face. An additional ability that distinguishes HSV I and HSV II is the ability to produce low levels of virus without vesicles and without destroying the cells producing the virus. This is called "viral shedding" and is normal for these viruses when they infect the sympathetic nervous system. This and other characteristics of this family of viruses make them "the likely suspects." The herpes family includes Varicella-Zoster (chicken pox-shingles), HSV I, HSV π, cytomegalovirus, Epstein-barr virus and several others that infect humans. Animals suffer diseases from this family including Marek's disease in fowl and pseudo-rabies in dogs, cats and cattle. Belief that the herpes virus can cause autoimmune diseases is consistent with the known behavior of the viruses in immune-suppressed individuals and the high prevalence in the general population. Varicella-Zoster (VZV) infects nearly 100% of the population above 10 years of age. Herpes Simplex π (HSV II) infects about 25 % of the population over 20 years of age. VZV infects most children within 5 years of birth and suffer a short episode of varicella (chicken pox). The immune system then suppresses the infection, which has infected the somatic sensory nerves, where it becomes latent only to reexpress itself after the age of 50 as episodes of shingles (Zoster). Usually this is a very localized presentation of gross vesicles on the skin usually involving only one, two or three nerves. This expression almost inevitably occurs in 5 immunosuppressed patients, such as AIDS or transplant patients when the immune system had lost much of its normal potency, regardless of the patients' age. HSV π is acquired by physical contact, usually sexual contact, with a person shedding the virus. It also represents in immunosuppressed patients, as the viral shedding vesicle eruptions. It is clear that the immune system, when working properly, prevents 10 virus production through vesicle formation, cell rupture and cell destruction. The competent immune system does not stop virus production of much smaller amounts of virus when formed in the cell and expelled through the cell membranes without vesicle formation and cell destruction. This is usually called "viral shedding. " Patients with known autoimmune disease(s) or related conditions who have 15 herpetic outbreaks are frequently placed upon the currently approved doses of acyclovir to treat the viral infection. While some report improvement in their subjective feelings regarding the symptoms of autoimmune disease, in several controlled studies the observers reported no difference between treated and control patients. Burroughs- Wellcome, the manufacturer of acyclovir strongly discourages 20 the use of higher doses by claiming that because poor solubility of acyclovir, no more than the amount absorbed from a single 800 mg dose administered every six hours (q6h) can be absorbed. The applicant proved that significantly higher blood levels than 1 μgm/ml (the currently approved desirable level) can be achieved in humans for acyclovir if enough is given to overcome the non-linear solubility. 25 These higher levels have been shown to be effective for treating autoimmune disease. Blood acyclovir levels of, e.g., over 6.5 μgm/ml have been repeatedly measured. Since the famciclovir dose response is linear in this range, relatively lower doses than acyclovir may accomplish adequate blood levels to suppress the production of "foreign" herpetic proteins. 30 One of the unique aspects of the method of this invention is the effect on the kidneys, as measured by creatinine clearance. It is generally believed that once kidney function has been significantly reduced, for example by inflammation, it will not return to normal. However, in the method of this invention, it has been discovered that kidney function that was significantly reduced by the autoimmune processes (e.g., creatinine clearance reduced from a normal of about 120 ml/min down to about 30 ml min) could be improved by administering a compound of Formula (I) (valacyclovir or acyclovir) or (It) (famciclovir) (e.g., up to about 60 ml/min from 30 ml min). This phenomenon has previously been unreported. Presumably, this very significant return of kidney function is due to the many glomeruii being simultaneously in various stages of autoimmune inflammation and destruction. Some of the glomeruii may be destroyed beyond return of normal functioning, because the clearance did not return to normal. (Also, pathologic examination of typical kidneys from autoimmune disease patients show glomeruii in various stages of inflammation of destruction, with the destroyed being more frequent in patients with less renal function.) Presumably, some of the glomeruii may be inflamed to the point of limited or not functioning, but are then able to resume more normal functioning when their inflammation subsided after 6 months of treatment with effective doses. This increase in creatinine clearance has been sustained and has improved over sustained periods of time. This is objective evidence that this technique is superior to all current therapies used to treat autoimmune disease that only occasionally show a transient 5 % increase in creatinine clearance when steroids are started to suppress the inflammation. This new treatment doesn't just slow the inevitable progression of autoimmune disease(s) (which is all conventional anti-inflammatory therapy can promise), it stops the stimulus for the immune system to cause the inflammation (the virus antigen production) and allows damaged and not destroyed tissue to repair itself with return of normal function. As the measured kidney function improved a parallel process occurred with a diminution of the visible inflammation, swelling, pain, grinding and clicks in the afflicted articular joints. Renal function tests that evaluate the severity of reduced kidney function can be found in The Merck Manual of Diagnosis and Therapy. Sixteenth Edition, Robert Berkow, M.D. Editor-in-Chief, 1992, Merck Research Laboratories at pp. 1654-1661. While any compounds that prevent viral shedding may be used in this invention, the compounds that are particularly useful for treating autoimmune diseases in accordance with this invention include those of Formula (I) and (II) below. Formula (I) is as follows: CH 2 -O-CH 2 -CH 2 OR where A is H or OH and OR is OH, a lower alkyl ester of 2-4 carbon atoms or -OC(O)CH(NH 2 )-R 3 15 where R 3 is H or lower alkyl of one to four carbons. 20 25 30 Representative lower alkyl esters include the acetate, propionate and butyrate esters. Of these the acetate is preferred. The compounds that are particularly useful is acyclovir, where A is OH and R is H (which is disclosed in U.S. Patent 4, 199,574 issued April 22, 1980 and which is incorporated herein by reference) and valacyclovir where A is OH and R is NH j I oc^c-α^CH^, I H especially the hydrochloride salt (which is disclosed in U.S. 4,957,924 issued Sept. 18, 1990 and which is incorporated herein by reference). Others include compounds of Formula (I) where A is OH and OR is OC(O)CH 2 (NH 2 ) or OC(O)CH(NH 2 )CH 3 . It should be noted that for both Formulae (I) and (II) where A or B is designated as OH, an alternative representation of the purine ring would be as follows: wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R t and R 2 is independently hydrogen, R 3 C or phosphate wherein 5 R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or R, and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group. The preferred compounds of Formula (II) are those wherein B is 10 hydrogen, OH or alkoxy of 1-6 carbons (particularly hydrogen or OH) and each of O II R, and R 2 is independently hydrogen or R 3 C where R 3 is alkyl of 1-6 carbons (e.g., acetyl). Penciclovir and famciclovir are preferred individual compounds. For purposes of this patent application the following definitions are applicable: 15 Alkyl of 1-6 carbons is a branched or straight chain hydrocarbon of 1 to 6 carbon atoms represented, e.g., by methyl, ethyl, n-propyl, i-propyl, n-butyl, t- butyl, 1 , 1-dimethyl-n-propyl, 3-hexyl, and the like. Alkyl of 1-4 carbons is similarly defined with only 1-4 carbons. Alkoxy of 1-6 carbons is a branched or straight chain alkyl attached to an 20 oxygen, i.e. , represented by the formula RO where R is a straight or branched chain alkyl of 1-6 carbon atoms. Representative alkoxy moieties include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, t-butoxy, hexyloxy, and the like. Aryl includes phenyl which may be optionally substituted with one or two groups selected from alkyl of one to six carbon atoms, alkoxy of one to six carbon 25 atoms or halo such as fluoro or chloro. In the case of compounds of Formula (H) wherein one of R, or R 2 is an acyl or phosphate group, the compound exists in two enantiomeric forms. The compounds useful in this invention include both an enantiomeres in isolated form and mixtures thereof. The compounds useful in this invention may be in crystalline form or as a hydrate, and it is intended that both forms are encompassed by the compounds represented by Formula (II) above. Examples of pharmaceutically acceptable salts of the compounds of Formulae (I) and (II) are acid addition salts formed with a pharmaceutically acceptable acid such as hydrochloric acid, orthophosphoric acid and sulfuric acid. When the compound of Formula (II) contains a phosphate group suitable salts include metal salts, such as aluminum, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammomum salts, for example those with lower alkylamines such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2- hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine. Suitable compounds of Formula (II) include; 2-amino-9-(4-hydroxy-3-hydroxymethylbut- 1 -yl)purine; 2-amino-9-(4-acetoxy-3-hydroxymethylbut- 1 -yl)purine; 2-amino-9-(4-acetoxy-3-acetoxymethylbut- 1 -yl)purine; 2-amino-9-(3-hydroxymethyl-4-methoxycarbonyloxybut- 1 yl)purine; 2-amino-9-[2-(2,2-dimethyl- 1 ,3-dioxan-5-yl)ethyl] purine; 2-amino-9-(4-propionyloxy-3-propionyloxymethylbut -1-yl) purine; 2-amino-9-(4-butyryloxy-3-hydroxymethylbut-l-yl)purine; 2-amino-9-(4-benzoyloxy-3-hydroxymethylbut- 1 -yl)purine; 2-amino-9-(4-hydroxy-3-hydroxymethylbut- 1 -yl)purine 4'-phosphate; 2-amino-9-(4-hydroxy-3-hydroxymethylbut- 1 -yl)purine 4':4"phosphate; and pharmaceutically acceptable salts thereof. The compounds of Formula (II), above are prepared in accordance with the procedures set forth in U.S. Patent 5,250,688 issued October 5, 1993; 5,246,937, issued September 21 , 1993 and 5,075,445 issued December 24, 1991, all of which patents are incorporated herein by reference. Another aspect of this invention is a pharmaceutical composition in unit 5 dosage form in combination with labelling instructions for treating autoimmune disease or associated insomnia in a mammalian subject. The pharmaceutical composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound chosen from those represented by Formula (I) or (II) as defmed hereinbefore and the labelling instructions provide for administering a 10 sufficient amount of the compound to the subject so that the blood plasma level of the active compound results in improvement to the subject's signs and symptoms indicating the presence of autoimmune disease. This is a key aspect of the invention in that before a compound can be approved for any particular use, it must be approved for marketing by the United States Food and Drug Administration. 15 Part of that process includes providing a label that will accompany the pharmaceutical composition which is ultimately sold. While the label will include a definition of the composition and such other items such as the clinical pharmacology, mechanism of action, drug resistance, pharmacokinetics, absorption, bioavailability, contraindications and the like, it will also provide the necessary 20 dosage, administration and usage. Thus, the combination of the drug with appropriate labelling instructions is important for the proper usage of the drug once it gets on the market. Another aspect of this invention is the use of a compound to prepare a pharmaceutical composition for treating autoimmune disease. The compound is represented by Formula (I) or (II) as defined hereinbefore. This aspect of the invention is simply directed at the utilization of these compounds to prepare the composition which will ultimately be used for treating autoimmune disease. In addition to and part of the process for preparing that pharmaceutical composition, the labelling and instructions for use of high levels of the compounds useful in this invention are included. Thus, such use of the compound in combination with providing instructions for use is part of another aspect of this invention. Still another aspect of the invention includes a method for detecting whether a mammalian subject exhibiting signs and symptoms of autoimmune disease can be treated to reduce such signs and symptoms by administering a therapeutically effective amount of the compound represented by Formula (I) or (II) as defined hereinbefore. This method comprises taking a body sample from the subject and detecting the presence or absence of the virus from the herpes simplex family. As the theory behind the treatment of autoimmune disease depends on the presence of the herpes virus, the method of detection which is part of this invention will be detecting the presence of that virus in order to enable one to treat the disease(s). There are many different presentations of autoimmune disease, literally hundreds. Some of these autoimmune disease may not be caused by the herpes virus. Testing for the presence of active viral shedding is likely to predict whether a specific autoimmune disease is likely to respond to this therapy. If the basis of the autoimmune disease is the presence of a herpetic virus, then taking a body sample from the subject and detecting the presence or absence of the virus in such a sample is encompassed within the invention. Preferably, the body sample is blood and the means for detection is a means that is commercially available, such as antibody tests or tests based on PCR (polymerase chain reaction). In carrying out this aspect of the invention it is difficult to detect the virus when it is latent or "hiding" in the sympathetic nervous system. Even if the virus is active, it may be difficult to detect 5 at low levels. The autoimmune reaction may not be directly reacting to the virus, but instead may be reacting to normal cell products, such as mitochondria or nuclear proteins, that the cells shed along with the virus particles in the non-vesicle non-destructive low level viral shedding, particularly well documented for HSV I and HSV π. Once those products are free from the cells, the immune system may 10 form antibodies to them that cause the inflammation. The detection may be of the virus itself, a component of the virus (such as free viral DNA) or of the by-products of the viral activity. Useful means of detecting HSV, HSV I and HSV II are available commercially and include (but are not limited to) the following antibody- based tests: 15 (1) The SYVA/MICROTRAK ® HSV 1/HSV 2 Culture Identification/Typing Test for pre CPE and CPE applications as described in U.S. 4,582,791 and U.S. 4,318,846; and (2) The SYVA/MICROTRAK HSV 1/HSV 2 Direct Specimen Identification/Typing Test for in vitro diagnostic use as described in 20 U.S. 4,582,791; and (3) The SYVA/MICROTRAK HSV Culture Identification Test for pre CPE and CPE applications as described in U.S. 4,582,791 and U.S. 4,318,846. All patents are incorporated by reference herein. Other tests may be apparent to those of skill in the art. Still another aspect of this invention is a method of treating insomnia in a mammalian subject where the insomnia is associated with autoimmune disease. In this aspect of the invention, the method comprises administering a therapeutically effective amount of a compound.of Formula (I) or (II) to a subject in need thereof, wherein the compounds represented by Formula (I) or (H) are described hereinbefore. The insomnia may be caused (1) directly by the pain of inflammation of end organ tissues (such as joints in rheumatoid arthritis), (2) directly by irritation of the pain nerves of the sympathetic nervous system (such as myofascial pain syndrome). Both of these caused pain that is perceived. However, we have found a third mechanism (3) by which sympathetic irritation can cause insomnia without perceived pain. (All of the mechanisms may be occurring simultaneously in varying intensities in a single patient, they are not mutually exclusive.) This is herpetic sympathetic irritation of the nerve fibers that control muscle tone. The irritation causes an unremitting hypertonus that is so great that the normal voluntary relaxation that initiates the sleep cycle cannot occur. This has been demonstrated in one patient with very severe insomnia. The pain was totally suppressed with narcotics, but the patient still could not relax his muscles and fall asleep. REM sleep could be achieved with or without narcotics present in concentrations adequate to control the pain when adequate blood levels of compounds of Formula (I) or (II) were achieved. When the blood levels of the compounds rose much above the levels achieved with conventional dosing the pain stopped first if it was not previously controlled by narcotics, then as the levels continued to rise the patient's muscles relaxed and the patient was able to achieve a significant number of REM cycles (the restorative phase of sleep) until after 4 to 6 hours the levels fell and the patient awakened. The patient reported feeling considerably less tired when sleep was accomplished using the methods of this invention. This is a marked improvement over narcotic treatment to control insomnia. If only narcotics are used 5 the patient usually could not achieve REM sleep, but if narcotics did allow sleep, it was of shorter duration, had fewer REM cycles and was not nearly as restorative as sleep achieved with this invention. The method of this invention suppresses both aspects of the sympathetic irritation that cause insomnia, the pain and the hypertonus. Narcotics suppress only the pain and are much less effective. 10 Hypnotic drugs (VALIUM, barbiturates, etc.) directly interfere with REM sleep even when they are present in adequate blood levels that unconsciousness (apparent sleep) does occur. Thus, the common treatments for insomnia such as hypnotics, sedatives and narcotics (if there is perceived pain present) do not offer adequate REM cycles for restorative sleep when the underlying cause is sympathetic 15 hyperactivity causing hypertonus. This new therapy is the first therapy to effectively and consistently allow adequate REM cycles to provide restorative sleep in patients suffering insomnia caused by (presumed viral) sympathetic irritation. Probably the best known and previously very misunderstood example of a person who suffered many years for lack of an effective treatment for insomnia even while 20 using adequate narcotics to control the pain and sympathetic chain irritation was Howard Hughes. Another example was Elvis Presley. (These opinions are based upon public information about these individuals' illnesses in light of the discoveries and inventions of this application). For purposes of this invention, it is to be understood that administering a therapeutically effective amount of a compound of Formula (I) or (II) encompasses a method wherein the compound itself is administered via a suitable pharmaceutical composition or a compound that converts into the compound of Formula (I) or (II) upon being administered to a subject in need thereof. For example, administering valacyclovir results in plasma levels of acyclovir, which is believed to be the active substance. Generally the compounds may be administered orally or intravenously (TV) but because of the ease of oral administration the oral route is preferred. A composition which may be administered by the oral route to humans may be compounded in the form of a syrup, tablet or capsule. When the composition is in the form of a tablet, any pharmaceutical carrier suitable for formulating such solid compositions may be used, for example magnesium stearate, starch, lactose, glucose, rice, flour and chalk. The composition may also be in the form of an ingestible capsule, for example of gelatin, to contain the compound, or in the form of a syrup, a solution or a suspension. Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerine, saline and water to which flavoring or coloring agents may be added to form syrups. The compounds may also be presented with a sterile liquid carrier for injection. In general suitable pharmaceutical carriers and methods of preparation can be found in Remington's Pharmaceutical Sciences. 18th Edition. In general, the type of pharmaceutical excipients and carriers are those that are used in the art for the compositions that already exist. For example, Famvir ® is provided as a pharmaceutical composition which contains hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide. For acyclovir, Zovirax ® capsules contain as an active ingredient acyclovir with inactive ingredients being cornstarch, lactose, magnesium stearate and sodium laurel sulfate, all of which is contained in a capsule shell of gelatin with FD&C Blue No. 2 and titanium dioxide. The tablets of 5 Zovirax ® at the 800 mg level contain as inactive ingredients FD&C Blue No. 2, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate. Zovirax ® is also available as a suspension which contains the active ingredient and the inactive ingredients methylparaben, propylparaben, carboxymethylcellulose sodium, flavor, glycerin, microcrystalline cellulose and 10 sorbitol. Valtrex ® capsules for oral administration contain valayclovir hydrochloride and the inactive ingredients, carnauba wax, colloidal silicon dioxide, crospovidone, FD&C Blue No. 2 Lake, hydroxypropylmethylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, Polysorbate ® -80, povidone and titanium dioxide. Other compositions may be apparent to one of skill in the art 15 upon reading the specifications. For intravenous infusion, the compounds may be provided as a sterile powder which is reconstituted with a sterile diluent. For these purposes, for example, in Zovirax ® sterile powder, lyophilized acyclovir sodium is used. Very high doses of compounds of Formulae (I) and (II) are needed to 20 provide a therapeutically-effective amount of the compounds. By administering the compounds of this invention at such levels, relief is seen of the signs and symptoms associated with autoimmune diseases. For example, the level of pain is reduced significantly, the swelling in the joints and the hands decreases, the butterfly rash is ameliorated and skin pain that might be related is also reduced. It is also been found in a patient with markedly reduced kidney function (as measured by creatinine clearance in ml/min) that prolonged treatment with these agents doubled the creatine clearance from about 30 to 60 ml min. Further treatment resulted in a clearance of about 66 ml/min. While any of the compounds encompassed within the generic Formulae of this invention can be used for treating the disease, generally, acyclovir, penciclovir, famciclovir and valacyclovir are preferred. Famciclovir is particularly preferred because it is more water soluble at body pH of 7.4 than other representative compounds such as acyclovir. The rate and frequency of dosing depends on the extent of the autoimmune conditions, individual tolerance and the particular drug chosen for administration. Generally a therapeutically effective amount is a dosage that is very high (i.e., about five to ten times higher) relative to the levels effective approved for the treatment of vesicles or somatic pain (not sympathetically-mediated pain) currently generally recognized to be caused by HSV such as HSV I or π or VZV. The therapeutically effective amount administered is sufficient to give the desired blood levels and ultimately the reduction of the signs and symptoms of the condition. The blood levels may vary from individual to individual but generally need to be between about 3 micrograms per ml to about 10 micrograms per ml, depending on the compound chosen. To achieve such a blood level, an amount administered on a daily basis will vary between about 4 grams per day to about 64 grams per day, although more or less may be administered depending on the activity and bioavailability of the particular compound administered. In general the compounds are administered at times throughout a day to maintain a blood level that will continue to ameliorate the autoimmune conditions and provide relief to the individual from the symptoms. Thus the dosing may be equal amounts provided 3 or up to 8 times a day depending on the individual and the compound chosen. Preferably the dosing is 3 to 6 times a day. In administering acyclovir, the material is administered at a rate of 5 about 20 grams per day to about 64 grams per day, preferably no more than about 50 grams/day. Generally, it is administered in four to six equal dosages a day taken throughout the day. This amount is needed because acyclovir is less soluble than valacyclovir, penciclovir or famciclovir. The amount of valacyclovir will be about 4 grams to about 8 grams per day, preferably about 6 grams per day divided 10 into equal doses and administered 3 to 4 times a day. The amount of famciclovir which is administered is about 4 grams to about 10 grams a day. Preferably it will be about four to seven and one-half grams per day, delivered about 4 to 6 times a day. The doses discussed in this application are all oral dosing. Parenteral dosing would be adjusted to achieve the desirable blood levels of between 4.5 μgm/ml and 15 10 μgm/ml. When attempts are made to raise the blood peak levels of acyclovir above, e.g., about 3 μgm/ml into the therapeutic range, there appears to be a transient irritation of all of the inflamed tissues during the rising phase of the dosage roughly between 10 and 30 minutes post intake. The amount of this increase is a function of the degree of underlying inflammation and is greatest in 20 previously untreated patients. The tissue most affected are the nerves of the sympathetic chain. Of the numerous nerves in the sympathetic chain this irritation effect is most marked and problematic on the nerves that send pain signals to the brain and maintain bowel muscle tension. During this "irritation phase" the intensity of the underlying pain or bowel spasm increases about 25 % for the duration of 20 minutes. This means that the most effective blood levels may not be achieved initially in previously untreated patients, due to the increased pain. The technique developed for acyclovir is to start a patient at doses roughly 4 times the present FDA-approved maximum dose 5 times per day. Then encourage the patient to "titrate to tolerance". For example, the patient starts with four 800 mg tablets 5 times per day. After one week the dose is increased 1 tablet (800 mg) per dose and continued if tolerated. If not tolerated during the "irritation phase" the dose is dropped back for 1 week then the incremental increase is tried again. When the patient can tolerate the dose it is continued at that level for 1 week and then a higher does is attempted. While end point may vary from patient-to-patient, in one example the patient had a peak blood level around 6.5 μgm/ml. It is expected that some patients may not be able to increase their doses for several weeks at a time. A wide amount of individual variation is expected depending upon many factors such as the localization of the areas of most severe pain, individual tolerance for pain, the determination of the patient to move into an effective therapeutic range and finally the amount of help provided to the patient in emotional support and pain relieving drugs. Without narcotic assistance, the patients can expect this process to take up to six months, sometimes with minimal detectable relief in the underlying symptoms. During this time the "irritation phase" will include signs of severe sympathetic chain irritation such as precipitous bowel evacuations with every dose for patients with irritable bowel syndrome, the same will occur in patients with interstitial cystitis and all will have marked night sweats and exacerbation of "trigger points". After months of therapy and the underlying inflammation is diminished markedly, this irritation phase diminishes accordingly. Famciclovir exhibits a similar irritation effect, but at an intensity only about 20% of acyclovir, and thus is preferred. The "titration to tolerance" for famciclovir is started at 1 gm (2 x 500 mg tabs) at 5 times per day. It is increased 500 mg (one tablet) per dose after 2 weeks. After 2 more weeks this is repeated. An adequate oral dose appears 5 to be 2 gms (4 x 500 mg tabs) 5 times per day. As with acyclovir the increases are withdrawn for 1 week if not tolerated because of the "irritation effect", then the increases are retried until tolerated. "Titrating to tolerance" is much easier with famciclovir than acyclovir. The following examples are given by way of representation of specific 10 administration modes, but should not be interpreted as limiting the scope of the claims in any way. 15 20 Example 1 This example sets forth the treatment of a patient with severe autoimmune disease signs and symptoms using high doses of acyclovir. A patient showing significant symptoms of autoimmune disease for about 15 years volunteered for treatment. Records confirmed the original diagnosis was made with the patient's anti nuclear antibodies (ANAs) at titers greater than 1 to 16 million and anti mitochondrial antibodies (AMAs) at titers greater than 1 to 4 million. The patient's creatinine clearance had dropped from a normal level of about 120 ml per minute to about 29 ml per minute. The patient showed moderate joint inflammation with pain, swelling, grinding and clicks in the hands and knees primarily. The patient also had severe myofascial pain and severe irritable bowel syndrome. In addition the patient was diagnosed as having HSV H. The signs and symptoms had developed to such an extent that the patient was unable to work and had very little sleep due to the excessive chronic, unremitting pain and muscular hypertonus caused by the disease condition. After treatment with high dosage of acyclovir in accordance with the method of this invention the patient found that the pain and inflammation was significantly reduced about 90% to the point where he again could sleep and function at a nearly normal rate. The initial treatment started with about 5 times the currently recommended maximum oral dosage acyclovir, with the initial dosage levels were about 4 grams which equated to twenty 200 gram capsules taken at one time. After three weeks of 20 capsules every six hours, the dosage eventually increased to a level of thirty 200g capsules every six hours. At about the third week the patient developed over a four to six hour period a gradual but approximately 80 % diminution in the previously chronic unremitting pain and spasm in the right T9 paraspinous muscle region. In addition over the first 3 weeks of the treatment the patient noticed a marked diminution in the tenderness and clicking of the joints in the hands and feet. In addition the faint butterfly mask on his face diminished noticeably but would come back fairly quickly if he failed to take a dose at intervals 5 longer than every six hours. Diminution of the "butterfly mask" of autoimmune disease in response to medication has not been previously reported. In this case the "butterfly mask" fluctuates inversely with the blood level of the drug administered. The dosage increased and a side effect after the patient was taking approximately 300 capsules per day, about 50 every six hours, was that he lost his ability to taste 10 salt, sweet, etc. After continuation for six months and at even higher doses, the ability to taste did return to normal. In addition, the patient noticed a thickening of the hair, particularly on the face and head. During this time, the pain reduced to such an extent that the patient could get two and a half to three hours sleep and at sometimes up to four and a half hours sleep without being awakened by the return 15 of significant pain as drug levels fell every 4 hours post dosage. The patient continued on dosing of acyclovir and found that the signs and symptoms could be reduced about 80% controlled by continued dosing at a rate of about ten 800 mg. tablets (8 grams) 5 to 6 times a day. Higher doses of acyclovir did not cause further decreasing in signs or symptoms. 20 Example 2 This example sets forth the continued treatment of the patient described in Example 1. After three years on acyclovir in higher doses described in Exhibit 1 , it was discontinued and famciclovir was started at the rate of about 2 grams 5 to 6 times a day. This is significantly less drug than was provided in Example 1. It is thought that less drug is needed than in Example 1 because famciclovir is more water soluble at body pH than acyclovir. By continued administration of the famciclovir at this level, the symptoms, including the pain and inflammation are controlled to be about 80-90% (as judged subjectively by the patient) of the original levels. It is found that if the dosage is eliminated, the signs and symptoms return to intolerable levels within about 12 hours. Example 3 By following the teaching of Examples 1 and 2, along with the teachings of the specification, other compounds, prepared as a suitable pharmaceutical composition are useful for treating autoimmune diseases in human subjects. Such compounds include penciclovir, valacyclovir, the glycine ester of acyclovir and the alanine ester of acyclovir. Further aspects of this invention may be apparent to those of skill in the art upon further contemplation of this disclosure.

Claims: THE SUBJECT MATTER CLAIMED IS: 1. A method of treating autoimmune disease in a mammalian subject, which method comprises administering a therapeutically effective amount of a compound of Formula (I) or (II) to a subject in need thereof, wherein (a) Formula (I) is CH 2 -0-CH 2 -CH 2 OR wherein A is H or OH, NI^ OR is OH, a lower alkyl ester of 2-4 carbon atoms or OC(O)C-R 4 , 15 I where R, is H or alkyl of 1-4 carbon atoms. (b) Formula (II) is 20 wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, NH 2 , -OH or -SH, 30 O II each of R, and R 2 is independently hydrogen, R 3 C- or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or R ] and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group. 2. The method of claim 1 wherein the amount of the compound administered is sufficient to raise the subject's blood plasma levels of the compound to about 3 μg/ml to about 10 μg/ml. 3. The method of claim 2 wherein the compound is represented by Formula (I) where A is H or OH and R is H, acetyl or valyl. 4. The method of claim 3 wherein the compound is acyclovir or valacyclovir. 5. The method of claim 4 wherein the level of acyclovir in the subject's blood plasma is about 4 μg/ml to about 10 μg/ml. 6. The method of claim 1 wherein the compound is represented by Formula (II) where B is H or OH and each of R, and R 2 is independently chosen from H or acetyl. 7. The method of claim 6 where in the compound is famciclovir or penciclovir. 8. The method of claim 7 wherein the famciclovir is administered in an amount sufficient to give a blood plasma level of active compound of about 3.5 μg/ml to about 10 μg/ml. 9. The method of claim 1 wherein the compound is administered orally. 10. The method of claim 9 wherein the compound is acyclovir and is administered at a rate of about 20 grams to about 50 grams per day. 5 11. The method of claim 9 wherein the compound is valacyclovir and is administered at a rate of about 5 grams to about 10 grams per day. 12. The method of claim 9 wherein the compound is famciclovir and is administered at a rate of about 4 grams to about 10 grams per day. 10 13. The method of claim 1 wherein the autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, or systemic sclerosis. 14. The method of claim 1 , wherein the level of pain associated with the 15 autoimmune disease and experienced by the subject is such that the patient is unable to function normally. 15. The method of claim 1 wherein the subject's kidney function has been significantly reduced below normal creatinine clearance levels. 20 16. The method of Claim 1 wherein the disease is chronic non-cancer pain. 25 30 17. A pharmaceutical composition in unit dosage form in combination with labelling instructions for treating autoimmune disease in a mammalian subject, wherein (a) the pharmaceutical composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound chosen from those represented by Formula (I) or (II) as follows: (i) Formula (I) is CH 2 -0-CH 2 -CH 2 OR wherein A is H or OH, ^ OR is OH, a lower alkyl ester of 2-4 carbon atoms or OC(O)C-R 4 , I H where R « is H or alkyl of 1-4 carbon atoms. (ii) Formula (II) is wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R< and R 2 is independently hydrogen, R 3 C- or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted 5 aryl; or R, and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group and (b) the labelling instructions provide for administering a sufficient amount of the compound to the subject so that the blood plasma level of the active 10 compound results in improvement to the subject's autoimmune signs and symptoms. 18. The combination of claim 17 wherein the labelling instructions provide for orally administering an amount of the compound that is sufficient for the subject to achieve blood plasma levels of about 3μg/ml to about lOμg/ml. 15 19. The combination of claim 18 wherein the compound is represented by Formula (I) where A is H or OH and R is H, acetyl or valyl. 20. The combination of claim 19 wherein the compound is acyclovir or 20 valacyclovir. 21. The combination of claim 20 wherein the level of acyclovir in the subject's blood plasma is about 4 μg/ml to about 10 μg/ml. 25 22. The combination of claim 21 wherein the compound is represented by Formula (TJ) where B is H or OH and each of R, and R 2 is independently chosen from H or acetyl. 23. The combination of claim 22 where in the compound is famciclovir or penciclovir. 24. The combination of claim 23 wherein the famciclovir is administered in an amount sufficient to give a blood plasma level of active compound of about 3.5 μg/ml to about 10 μg/ml. 25. The combination of claim 24 wherein the compound is administered orally. 26. The combination of claim 25 wherein the compound is acyclovir and is administered at a rate of about 20 grams to about 50 grams per day. 27. The combination of claim 25 wherein the compound is valacyclovir and is administered at a rate of about 4 grams to about 8 grams per day. 28. The combination of claim 25 wherein the compound is famciclovir and is administered at a rate of about 4 grams to about 10 grams per day. 29. The combination of claim 18 wherein the autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, or systemic sclerosis. 30. The combination of claim 18, wherein the level of pain associated with the autoimmune disease and experienced by the subject is such that the patient is unable to function normally. 31. The combination of claim 18 wherein the subject's kidney function has been significantly reduced below normal creatinine clearance levels. 32. The combination of claim 18 wherein the disease is chronic non- cancer pain. 33. A method of treating insomnia associated with autoimmune disease in a mammalian subject, which method comprises administering a therapeutically effective amount of a compound of Formula (I) or (II) to a subject in need thereof, wherein (a) Formula (I) is CH 2 -0-CH 2 -CH 2 OR wherein A is H or OH, ^2 OR is OH, a lower alkyl ester of 2-4 carbon atoms and OC(O)C-R 4 , 15 I where R 4 is H or alkyl of 1-4 carbon atoms. 20 (b) Formula (H) is wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R, and R 2 is independently hydrogen, R 3 C- or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or R, and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group. 34. The method of claim 33 wherein the amount of the compound administered is sufficient to raise the subject's blood plasma levels of the compound to about 3 μg/ml to about 10 μg/ml. 35. The method of claim 34 wherein the compound is represented by Formula (I) where A is H or OH and R is H, acetyl or valyl. 36. The method of claim 35 wherein the compound is acyclovir or valacyclovir. 37. The method of claim 36 wherein the level of acyclovir in the subject's blood plasma is about 4 μg/ml to about 10 μg/ml. 38. The method of claim 33 wherein the compound is represented by Formula (II) where B is H or OH and each of R, and R 2 is independently chosen from H or acetyl. 39. The method of claim 38 where in the compound is famciclovir or 5 penciclovir. 40. The method of claim 39 wherein the famciclovir is administered in an amount sufficient to give a blood plasma level of active compound about 3.5 μg/ml to about 10 μg/ml. 10 41. The method of claim 33 wherein the compound is administered orally. 42. The method of claim 41 wherein the compound is acyclovir and is 15 administered at a rate of about 20 grams to about 50 grams per day. 43. The method of claim 41 wherein the compound is famciclovir and is administered at a rate of about 4 grams to about 10 grams per day. 20 44. The method of claim 41 wherein the compound is valacyclovir and and is administered at a rate of about 4 grams to about 8 grams per days. 45. The method of claim 33 wherein a high level of pain is associated with the autoimmune disease. 25 46. The method of claim 33, wherein a level of pain is associated with the autoimmune disease and experienced by the subject at such a level that the patient is unable to function normally. 30 47. The method of Claim 33 wherein the disease is chronic non-cancer pain. 48. Use of a compound to prepare a pharmaceutical composition for treating autoimmune disease wherein the compound is represented by Formula (I) and (II) as follows (a) Formula (I) is CH 2 -0-CH 2 -CH 2 OR wherein A is H or OH, NH 2 OR is OH, a lower alkyl ester of 2-4 carbon atoms and OC(O)C-R 4 , where R, is H or alkyl 1-4 carbon atoms. H (b) Formula (H) is wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, NH 2 , -OH or -SH, O each of R, and R 2 is independently hydrogen, R c or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or Rj and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group. 49. The use of claim 48 wherein the compound is represented by Formula (I) where A is H or OH and R is H, acetyl or valyl or by Formula (H) where B is H or OH and each of R, and R 2 is independently chosen from H or acetyl. 50. The use of claim 49 wherein the compound is acyclovir, valacyclovir 10 or famciclovir. 51. The use of claim 48 wherein the composition is a unit dosage form for oral administration. 15 52. A method for detecting whether a subject exhibiting signs and symptoms of autoimmune disease can be treated to reduce such signs and symptoms by administering a therapeutically effective amount of a compound represented by Formula (I) or (II) as follows: (a) Formula (I) is 20 CH 2 -0-CH 2 -CH 2 OR wherein NH * , A is H or OH, OR is OH, a lower alkyl ester of 2-4 carbon atoms and OC(O)C-R 4 30 where R, is H or alkyl 1-4 carbon atoms. H (b) Formula (II) is wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R, and R 2 is independently hydrogen, R 3 C- or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or R- and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or cyclic phosphate group, wherein such method comprises taking a body sample from the subject and detecting the presence or absence of a virus from the Herpes simplex family. 53. The method of claim 52, wherein the body sample is blood, cerebrospinal fluid, joint fluid, other body fluids or tissue. 54. The method of claim 52, wherein the means for detection is antibody- based. 55. A method of treating autoimmune disease in a mammalian subject, which method comprises administering a therapeutically effective amount of a compound that is active against herpes virus at levels sufficient to prevent the herpes virus from viral shedding to reduce the signs and symptoms of the autoimmune disease. 56. A pharmaceutical composition in unit dosage form in combination with labelling instructions for treating insomnia associated with autoimmune disease in a mammalian subject, wherein (a) the pharmaceutical composition comprises a pharmaceutically 10 acceptable excipient and a therapeutically effective amount of a compound chosen from those represented by Formula (I) or (II) as follows: (i) Formula (I) is CH 2 -0-CH 2 -CH 2 OR 20 wherein A is H or OH, NH-. OR is OH, a lower alkyl ester of 2-4 carbon atoms or OC(O)C-R 4 , H where R, is H or alkyl of 1-4 carbon atoms. 25 (ii) Formula (II) is wherein B is hydrogen, chlorine, alkoxy of 1-6 carbons, phenoxy, phenylalkyloxy, - NH 2 , -OH or -SH, O II each of R, and R 2 is independently hydrogen, R 3 C- or phosphate wherein R 3 is an alkyl of 1-6 carbons, alkoxy of 1-6 carbons or optionally substituted aryl; or R, and R 2 are joined together to form a cyclic acetal, a cyclic carbonate or a cyclic phosphate group and (b) the labelling instructions provide for administering a sufficient amount of the compound to the subject so that the blood plasma level of the active compound results in allowing the subject to enter into a sleep cycle with reduced hypertonus. 57. The combination of claim 56 wherein the labelling instructions provide for orally administering an amount of the compound that is sufficient for the subject to achieve blood plasma levels of about 3μg/ml to about lOμg/ml. 58. The combination of claim 57 wherein the compound is represented by Formula (I) where A is H or OH and R is H, acetyl or valyl. 59. The combination of claim 58 wherein the compound is acyclovir or valacyclovir. 60. The combination of claim 59 wherein the level of acyclovir in the subject's blood plasma is about 4 μg/ml to about 10 μg/ml. 61. The combination of claim 60 wherein the compound is represented by Formula (H) where B is H or OH and each of R, and R 2 is independently chosen from H or acetyl. 62. The combination of claim 61 where in the compound is famciclovir or penciclovir. 63. The combination of claim 62 wherein the famciclovir is admimstered in an amount sufficient to give a blood plasma level of active compound of about 3.5 μg/ml to about 10 μg/ml. 64. The combination of claim 63 wherein the compound is administered orally. 10 65. The combination of claim 64 wherein the compound is acyclovir and is administered at a rate of about 20 grams to about 50 grams per day. 66. The combination of claim 64 wherein the compound is valacyclovir and is administered at a rate of about 4 grams to about 8 grams per day. 15 67. The combination of claim 64 wherein the compound is famciclovir and is admimstered at a rate of about 4 grams to about 10 grams per day.

Inventors: EXLEY RAY W, EXLEY, RAY, W.
Applicants: EXLEY RAY W, EXLEY, RAY, W.
Application year: 1995
Main classification: A61K31
IPC codes: A61K31